Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Heart Failure 1Cardiotoxicity 1

Interventions

Doxorubicin 6Dexrazoxane 6Razoxane 5Vincristine 4Cyclophosphamide 4Radiotherapy 3Etoposide 3Prednisone 2Methotrexate 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Carvedilol 2Bleomycin 2schizandrin 1pegfilgrastim 1hydrocortisone hemisuccinate 1fructus schizandrae, radix ginseng, radix ophiopogonis drug combination 1empagliflozin 1Watchful Waiting 1VAP-cyclo protocol 1Trastuzumab 1Taxes 1Tamoxifen 1Rituximab 1Ramipril 1Radiation 1Prednisolone 1Paclitaxel 1Observation 1Neoadjuvant Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Cardiotoxicity × Ivabradine × Clear all
NCT04030546 2019-12-18

Ivabradine to Prevent Anthracycline-induced Cardiotoxicity

Vilnius University

Phase 3 Unknown
128 enrolled

Heart Failure, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡